
    
      This Phase I study is an open-label, dose-escalation trial designed to assess the safety,
      tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the novel
      anti-cancer compound, GZ17-6.02. GZ17-6.02 is administered orally to patients with advanced
      solid tumors or lymphoma.
    
  